Actively Recruiting
Risk of Metachronous Findings After Detection of Serrated Lesions and High-grade Dysplasia With Surveillance Delay
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2025-02-11
730
Participants Needed
1
Research Sites
148 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary aim of this study is to determine the rate of total metachronous advanced neoplasia (TMAN) detection after index detection of serrated lesions (SL) \[sessile serrated polyps (SSPs), traditional serrated adenomas (TSAs)\], and metachronous high-risk adenoma (HRA) after index detection of high-grade dysplasia (HGD). We will use the database of patients diagnosed with SL or HGD at index colonoscopy with a delay in surveillance and determine the risk of advanced lesions (especially high-risk lesion and CRC detection) of these delayed colonoscopies. The aim is to determine the effects of breach of continuity of care in these patients.
CONDITIONS
Official Title
Risk of Metachronous Findings After Detection of Serrated Lesions and High-grade Dysplasia With Surveillance Delay
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 45 to 80 who underwent colonoscopy from 2009 to 2022 at Montreal University Hospital Center (CHUM) with one or more serrated lesions or high-grade dysplasia detected at initial colonoscopy
- Patients lacking follow-up colonoscopy within or beyond the surveillance interval recommended by 2020 US Multi Society Task Force guidelines
You will not qualify if you...
- Patients diagnosed with inflammatory bowel disease
- Patients with hereditary colorectal cancer syndromes
- Patients diagnosed with colorectal cancer at initial colonoscopy
- Patients with serrated polyposis syndrome
- Patients with life expectancy too short to benefit from colonoscopy
- Patients whose follow-up colonoscopy is not yet due according to US Multi Society Task Force guidelines unless they have both high-risk adenoma and serrated lesions with index colonoscopy more than one year ago
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
Actively Recruiting
Research Team
D
Daniel von Renteln, MD, PhD
CONTACT
J
Julie Fleury
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here